Form 8-K - Current report:
SEC Accession No. 0001628280-24-019053
Filing Date
2024-04-29
Accepted
2024-04-29 16:53:33
Documents
13
Period of Report
2024-04-29
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K cpix-20240429.htm   iXBRL 8-K 31525
  Complete submission text file 0001628280-24-019053.txt   155756

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cpix-20240429.xsd EX-101.SCH 2013
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cpix-20240429_lab.xml EX-101.LAB 21885
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cpix-20240429_pre.xml EX-101.PRE 12611
16 EXTRACTED XBRL INSTANCE DOCUMENT cpix-20240429_htm.xml XML 2827
Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Filer) CIK: 0001087294 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33637 | Film No.: 24892132
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)